Tag: Medtronic
CMS grants transitional pass-through payment for Medtronic’s Symplicity Spyral and Recor’s...
The Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for Medtronic's Symplicity Spyral renal denervation (RDN) catheter and Recor...
ABRE subanalysis highlights obesity ‘paradox’ in post-venous stenting outcomes
Results from a subset analysis of the ABRE study have shown that patients in three out of the six World Health Organisation (WHO) body...
The top 10 most popular Vascular Specialist stories of May 2024
In April, the most read stories from Vascular Specialist include new data from the C-GUARDIANS pivotal investigational device exemption (IDE) trial presented at the...
Nitinol stents placed in iliac veins “not associated with prolonged back...
In a retrospective review of over 600 patients who underwent iliac vein stent placement, the development of back pain was found to be unrelated...
First patient enrolled in HERCULES randomized trial comparing ESAR and EVAR
The first patient has been enrolled into the HERCULES trial, which compares endosuture aneurysm repair (ESAR) to standard endovascular aneurysm repair (EVAR) in the treatment of abdominal aortic...
TRANSCEND 36-month data “continue to demonstrate safe and effective performance” of...
Peter Schneider (University of California San Francisco, San Francisco, USA) recently presented 36-month data from Surmodics' TRANSCEND clinical trial at the VEITHsymposium 2023 (14–18...
First patient treated in global strategic collaboration involving Cydar Maps technology
Cydar Medical has announced the successful treatment of the first patient in a strategic collaboration with Medtronic. The collaboration, which spans 40 sites across...
The top 10 most popular Vascular Specialist stories of January 2023
In January 2023, most popular among the Vascular Specialist readers were several stories from the recent Southern Association for Vascular Surgery meeting, including a report of data shared to demonstrate...
VQI study leader highlights virtue of multispecialty gathering of best longitudinal...
Daniel Bertges, MD, talks to Vascular Specialist about recent findings from his work investigating the IN.PACT Admiral drug-coated balloon (DCB). He related how they...
Medtronic announces first enrollment in head-to-head global randomized trial evaluating durability...
Medtronic has announced the first patient enrollment in the ADVANCE trial, a head-to-head randomized controlled trial of two leading aortic stent graft systems, the...
SurVeil DCB demonstrates sustained durability of safety, efficacy endpoints in TRANSCEND
In the TRANSCEND clinical trial, the SurVeil drug-coated balloon (DCB; Surmodics) demonstrated "excellent efficacy and safety" out to 24-month follow-up. This is according to...
Abre stent data show ‘struggle to maintain patency’ among post-thrombotic syndrome...
The Abre venous stent demonstrated three-year primary patency rates of 97.1%, 76.5% and 70.4% respectively for non-thrombotic iliac vein lesion (NIVL), acute deep vein...
ABRE clinical study 36-month data show ‘long-term durability’ of venous stent...
Medtronic has announced the 36-month final results from the ABRE clinical study. The purpose of the ABRE clinical study was to evaluate the safety and...
Medtronic gains FDA nod for IN.PACT 018 DCB
Medtronic has announced approval from the Food and Drug Administration (FDA) for the IN.PACT 018 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, a drug-coated...
CX 2022: IN.PACT AV DCB shows sustained and superior performance compared...
New randomized controlled data demonstrating the sustained and superior performance of IN.PACT AV drug-coated balloons (DCBs) compared to percutaneous transluminal angioplasty (PTA) through 36...
Cydar Medical announces strategic collaboration with Medtronic
Cydar Medical recently announced it has entered a strategic collaboration with Medtronic. Under the pilot arrangement, Cydar’s EV Maps software will be introduced to up...
Medtronic issues voluntary recall for subset of IN.PACT Admiral and IN.PACT...
Medtronic recently voluntarily recalled a subset of its IN.PACT Admiral and IN.PACT AV paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheters due to the potential...
The top 10 most popular Vascular Specialist stories in January
January’s top 10 includes “Our forever plague,” a combined editorial by Malachi Sheahan III, MD, our medical editor, on fake news and science, and...
Medtronic issues voluntary recall for TurboHawk Plus directional atherectomy system
On Feb. 7, Medtronic issued a notice emphasizing that the same warnings and precautions issued for the HawkOne directional atherectomy system also apply for...
ISET 2022 audience hears latest data on endovascular therapies
At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results...
IN.PACT Admiral DCB performs well across wide range of clinical, anatomical...
In a pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness, the IN.PACT Admiral DCB (Medtronic) performed well across a broad range of clinical, anatomical...
Benefits of percutaneous fistula creation further bolstered by five-year Ellipsys data
The Ellipsys vascular access system (Avenu Medical/Medtronic) can be used to easily and safely create durable percutaneous arteriovenous fistulas (pAVFs) for haemodialysis—with new, long-term...
VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...
European launch: Medtronic receives CE mark for 200mm and 250mm IN.PACT...
Medtronic has announced the European launch of the 200mm and 250mm IN.PACT Admiral drug-coated balloons (DCBs) following CE mark approval. The product is intended to treat long...
Medtronic issues updated patient management recommendations on Valiant Navion recall
Medtronic has announced that it has sent physicians updated patient management recommendations related to its voluntary recall of the Valiant Navion thoracic stent graft...
Medtronic recalls unused Valiant Navion thoracic stent graft system
Medtronic has voluntarily issued a global recall of its Valiant Navion thoracic stent graft system and informed physicians to immediately cease use of the...
SVS acknowledges industry partners springing to aid of vascular community
It has recently come to the attention of the Society for Vascular Surgery (SVS) that many of our industry partners are generously donating equipment...
‘Excellent’ long-term results after EVAR using Endurant stent graft in 180...
Results from a real-world experience over more than 10 years using the Endurant stent graft (Medtronic) demonstrate that it is safe and effective,...
VenaSeal superior for management of chronic venous insufficiency, finds systematic review
According to a network meta-analysis, the VenaSeal system by Medtronic is “a promising therapeutic option for anatomic success at six months.” The study, published...
COVID-19: Ventilator manufacturers unite to form training alliance
Several of the world’s ventilator manufacturers have formed a Ventilator Training Alliance (VTA) in partnership with Allego to create a mobile app that frontline...
Medical device companies join fight against COVID-19
Medtronic is sharing an older version of its Puritan Bennett ventilator for free in a bid to help ramp up production of the key...